| Aspect | PRN-4011 | Existing Drugs (e.g., GSK2606414, Buphenyl) | | :--- | :--- | :--- | | | High allosteric binding to PERK; low off-target kinase activity | Older PERK inhibitors often cross-react with other kinases (e.g., JAK2, SRC). | | Toxicity | No significant pancreatic or weight loss in animal models | First-gen PERK inhibitors caused hyperglycemia and exocrine pancreas toxicity. | | Oral Bioavailability | 68% | <20% for many prior UPR modulators. | | CNS Penetration | Moderate (35% CSF/plasma ratio) | Poor to negligible. |
Stay updated on PRN-4011 developments by following the peer-reviewed literature in journals such as The Journal of Neurochemistry and Stroke. prn-4011